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Background and Abstract: 
 
In 2004 there were an estimated 1.7 million deaths from tuberculosis (TB).  Due 
to improper use of antibiotics, many drug resistant forms of Mycobacterium tuberculosis 
(M.tb), the causative agent of TB, have risen around the world, making this disease a 
leading cause of death among infectious disease agents.  M.tb remains dormant in healthy 
hosts and becomes active when the immune system is weakened.  The bacterium is an 
intracellular pathogen of macrophages.  M.tb uses complement receptor 3 (CR3), among 
others, for complement-opsonized and non-opsonized phagocytosis by human 
macrophages and evades host defenses by replicating intracellularly in the phagosome.  
The polysaccharide β-glucan has been found to competitively inhibit binding to CR3 by 
incoming pathogens and allows for their clearance through other mechanisms. For 
example, it has been shown to up-regulate the production of pro-inflammatory cytokines 
and promote both anti-microbial and anti-tumor activities, most likely through its binding 
to the β-glucan receptor, Dectin-1, expressed on host macrophages.  Because of its effects 
on CR3 and the innate immune response, we hypothesize that β-glucans would enhance 
activity against M.tb by inhibiting CR3-mediated phagocytosis and up-regulating human 
macrophage microbicidal activities.  The effects of β-glucans were tested on human 
monocyte-derived macrophages (MDMs) which were obtained by allowing 
differentiation of blood monocytes isolated from healthy donors.  The MDMs in 
monolayer culture were infected with the attenuated Mycobacterium bovis BCG (vaccine 
strain), a highly genetically-related model bacterium to M.tb, in the presence or absence 
of different β-glucan preparations [PGG (soluble) and WGP (insoluble)] supplied from 
Biothera (Eagan, Minnesota).  After a 2 h infection, the infected cell monolayers were 
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fixed and mycobacteria were stained with auramine-rhodamine dye to assess bacterial 
association (bound and internalized) with macrophages by fluorescence microscopy.  
Alternatively, following infection, the MDMs were lysed at different time points (24 h, 
48 h, 72 h), the lysates spread on agar plates for bacterial growth, and colony forming 
units (CFUs) determined to assess bacterial intracellular survival.  This in vitro study 
produced preliminary results showing an antimicrobial effect by β-glucans against M. 
bovis BCG in MDMs as demonstrated by both bacterial survival and cell association 
assays.  This preliminary study shows that β-glucans may possess therapeutic potential to 
treat TB infection.   
 
 
 
Introduction: 
 
 
Tuberculosis as a Disease: Tuberculosis (TB) is a contagious disease spread from 
infected individuals through aerosol droplets which are inhaled by healthy humans in 
close proximity and deposited into the lungs.  One third of the world’s population is 
infected with the bacterium (bacillus) which causes TB and nearly 2 million people 
worldwide die annually from this disease (1).  In the majority of infected individuals, the 
bacillus will remain dormant for years without noticeable symptoms (latent TB), and 
reactivate when the host’s immune system is compromised (reactivation TB) (Figure 1).  
TB is the second most deadly infectious disease in the world (23,25).  When active, the 
TB bacillus forms a particularly lethal combination with human immunodeficiency virus 
(HIV) in AIDS patients due to the host’s weakened immune system.  The high rate of 
mortality of HIV-infected individuals in African countries correlates directly with an 
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increase in TB-afflicted individuals in this region since 1990 (1).  In 1993, the rise of TB 
was so severe that the World Health Organization (WHO) declared the disease a global 
health emergency.  Due to improper use of antibiotics, drug resistant TB has arisen 
worldwide.  Bacterial strains which cause TB, showing resistance to at least one of the 
two most commonly used TB drugs, isoniazid and rifampin, have been found in every 
country that has been surveyed by WHO.  Multi-drug resistant TB (MDR-TB), 
unaffected by both isoniazid and rifampin, has arisen worldwide making up 20% of 
known cases (2).  In 2005, extensively drug resistant TB (XDR-TB) was first reported as 
having resistance to isoniazid and rifampin, to fluoroquinolones, and to at least one of the 
following second line injectable drugs: amikacin, capreomycin, or kanamycin.  XDR-TB 
makes up about 3% of TB cases worldwide and has increased in foreign-born individuals 
in the U.S. since 1999 (3).  The gradual rise in MDR-TB and the recent emergence of 
XDR-TB add to the continued difficulty in controlling the spread of this disease.  The 
increasing rate of developing resistant strains makes the need for new therapies essential 
in combating TB worldwide.  
 
Mycobacterium tuberculosis as a Causative Organism:  TB is caused by the slow- 
growing, acid-fast bacillus Mycobacterium tuberculosis (M.tb).  M.tb is an obligate 
aerobic bacterium and an intracellular pathogen of macrophages.  It enters the human 
body through inhalation and deposits into the oxygen-rich alveolar sacs of the lungs (25).  
One of the first groups of cells that bacteria come in contact within the lungs is alveolar 
macrophages.   These phagocytic cells have unique attributes which make them efficient 
in combating incoming particles in the airways with controlled immune responses (5).  
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Phagocytosis of the bacteria, maturation of the bacterial phagosome, and generation of 
pro-inflammatory responses are critical aspects in controlling M.tb infection (25).  
Microbes are recognized by pattern recognition receptors (PRRs) on cells of the immune 
system, including neutrophils, dendritic cells, natural killer cells and macrophages.  
These PRRs detect structural components on pathogens and stimulate an immune 
response to inhibit infection.  Among the PRRs important for the recognition of M.tb by 
alveolar macrophages are the mannose receptor (MR), Complement Receptor 3 (CR3) 
and Toll-like receptors [TLRs] (5,36).  Both the MR and CR3 have been found to play a 
critical role in the phagocytosis of M.tb by human macrophages (17,26).  The ligand for 
the MR is mannose-capped surface unit lipoarabinomannan, (ManLAM) found on M.tb 
and Mycobacterium bovis BCG (M. bovis BCG) (17,27).  M.tb is phagocytosed by CR3 
in both a C3bi opsonic and non-opsonic-dependent manner (6).  Once phagocytosed by 
alveolar macrophages, most bacteria are generally degraded by acidic hydrolases upon 
fusion with the lysosomal compartment within the macrophage (phagolysosome fusion).  
Macrophages also degrade engulfed bacteria through microbicidal functions mediated by 
cytokines.  These functions include an oxidative burst through generation of reactive 
oxygen intermediates (ROI) along with reactive nitrogen intermediates [RNI] (25).  Non-
phagocytic TLRs activate inflammatory cytokines and development of antigen-specific 
immunity upon ligand binding with M.tb.  Notably, TLR2 (dependent on myeloid 
differentiation factor 88 or MyD88) has been found to work in concert with other 
receptors to produce tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), 
cytokines important in initiating a host inflammatory response (15).  TNF-α is a 
macrophage activating factor which generates nitric oxide, a critical component in 
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destroying pathogens.  Recent studies have shown that TLR2-deficient mice have 
impaired immune responses to mycobacterial species (15), along with decreased TNF-α 
secretion (36).  The outcome of mycobacterial infection within the lungs has been 
identified to be dependent on TLR2 activation (10).   
M.tb’s pathogenicity comes from its ability to evade immune responses.  This 
organism has evolved into an extremely adaptive pathogen, replicating and avoiding host 
defense mechanisms within alveolar macrophages (5).  Phagocytosis of M.tb by alveolar 
macrophages is the first step in determining whether the bacillus will escape the immune 
response (25).  M.tb has developed different strategies by which it enters mononuclear 
phagocytes and evades phagolysosome fusion. As stated above, the MR, CR3 and TLRs 
mediate the macrophage-mycobacterium interaction upon entry of M.tb within the lungs.  
M.tb phagocytosis by human macrophages via the MR-ManLAM pathway has been well 
documented (17,27).  Entry through this route allows a safe haven for the mycobacteria to 
reside within altered mycobacterial phagosomes that do not mature into phagolysosomes 
(16).  The MR is highly expressed on alveolar macrophages and the MR-mediated 
phagocytosis of M.tb is known to produce anti-inflammatory cytokines, and reduce nitric 
oxide and oxidant radical production (6).  Thus, while the MR is efficient in removing 
routinely encountered airborne particles in the airways, it seems to provide a critical role 
for M.tb survival. 
Human macrophages, including MDMs, also express the β-glucan receptor, 
Dectin-1, which has been well demonstrated to produce pro-inflammatory cytokines upon 
ligation with its ligand, β-glucan (34).  β-glucans are present in certain fungal cell walls, 
and studies suggest that another ligand for Dectin-1 may exist on attenuated or avirulent 
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mycobacteria (13,36).  However, the virulent H37Rv strain of M.tb does not appear to 
have a Dectin-1 ligand (36).  Therefore, the presence of Dectin-1 ligands appears to relate 
to the pathogenicity of the invading Mycobacterium spp.   
            
Beta-Glucan Particles as Therapeutic Agents:  β-glucan is a polysaccharide commonly 
found in oats, barley, and yeast.  Its basic structure consists of about 20-30 β-1,3-D-
glucose units with branched side chains of either β-1,3 or β-1,6-glucose molecules 
(Figure 2).  The exact structure of a β-glucan particle depends on its source, varying in 
solubility and branching.  β-glucans are commonly found in the cell walls of fungi.  
Interestingly, these polysaccharides become exposed on the fungal cell wall only during 
the replicative periods of swelling and germ tube formation (13).  Certain fungal species 
cause infections in humans via entry through the respiratory tract.  Because of this, 
alveolar macrophages have adapted a mechanism for recognizing and eliminating these 
organisms when they are inhaled by the host and come in contact with lungs.   
β-glucans are recognized on lung alveolar macrophages through interaction with the non-
opsonic C-type lectin, Dectin-1 as noted above (31).  Among phagocytic cells, alveolar 
macrophages exhibit the highest surface expression of Dectin-1, speculated as an 
evolutionary mechanism caused by the interaction of the lung environment with fungi 
(30).  After binding to its β-glucan ligand, Dectin-1 stimulates immune responses to 
combat fungal infection.  β-glucan binding to Dectin-1 is known to stimulate increased 
TNF-α  and IL-6 secretion by macrophages, resulting in phagocytosis, inflammation and 
antimicrobial defenses (8,13,36).  Although currently a topic of debate, Dectin-1 is 
thought to work in coordination with TLRs to up-regulate an immune response (36). CR3 
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was previously identified as a β-glucan receptor, stimulating cytotoxic activity of 
phagocytes and host defense mechanisms (35).   
 Over the past thirty years β-glucan supplements have been experimentally tested 
to combat various human diseases.  The idea is that β-glucan molecules will up-regulate 
an immune response which could have been suppressed or eluded by the pathogen.  The 
most common forms of supplementary β-glucan are: insoluble whole glucan particle 
(WGP), a 1,3/1,6- β-glucan purified from Saccharomyces cerevisiae and soluble poly-1-
6-β-D-glucopyranosyl-1-3- β-D-glucopyranose (PGG), formed by acid hydrolysis of 
WGP (19).  β-glucan particles have been used as anti-tumor agents, combating metastasis 
through the increased production of natural killer and interferon-γ-positive cells (18). 
These compounds have also been found to fight against pathogens outside of the fungal 
realm.  β-glucan has been shown to protect mice against Streptococcus pneumoniae, 
Staphylococcus aureus, and Escherichia coli (12,21,22).  In all cases, a decreased 
bacterial load was observed following β-glucan treatment.  In an in vivo study most 
relevant to our in vitro experiments, β-glucan administration has been tested on mice 
intravenously infected with M. bovis BCG.  The study provided evidence that β-glucan 
molecules initiate a defense strategy to enhance the host immune response against 
mycobacterial infection (11).   
 M. bovis BCG is an attenuated strain of Mycobacterium bovis, the causative agent 
of TB in cattle.  M. bovis BCG is currently used as a protective vaccine against TB in 
humans throughout the world, showing variable results (24).  This strain retains some 
antigenic properties, while its virulence in humans has been attenuated (4).  The genomic 
sequences of M. bovis BCG and M.tb are > 99.95% identical (7).  The structure of the 
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MR ligand, ManLAM, on M. bovis BCG resembles that found on M.tb, providing 
evidence for similar macrophage interactions between the two strains (32).  Because of 
their similar interactions with human macrophages, M. bovis BCG can be used 
experimentally as a model to study the effects on M.tb infection.   
 Due to the increased rates of MDR-TB and XDR-TB, new therapies are needed 
for TB disease.  β-glucan particles PGG and WGP could bring a solution to this problem 
as they have shown the ability to fight various bacterial diseases including those caused 
by mycobacterial species.  As stated above, treatment with β-glucan protected mice from 
M. bovis BCG infection (11).  However, it is crucial to use human cells in order to further 
research and development of a therapy for human mycobacterial diseases, especially TB.  
Such cells are known to be significantly different from those found in rodents. In our 
investigation, we examined the association and antimicrobial effects that PGG and WGP 
have on M. bovis BCG upon infection of human monocyte-derived macrophages.  This 
study provides evidence for decreased macrophage association of M. bovis BCG along 
with decreased survival within macrophages when MDMs were pretreated with the β-
glucan compounds. 
 
 
 
Methods and Materials: 
 
Mycobacterial strains, Media and β-Glucan Compounds: M. bovis BCG (Pasteur strain) 
was seeded onto DifcoTM  7H11 agar (Benton, Dickinson and Company) plates.  The 
plates were incubated at 37ºC/5% CO2 for 10-12 days to allow for bacterial lawn 
formation.  These bacterial lawns were then used to prepare M. bovis BCG single cell 
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suspensions for infection of macrophages.  The β-glucan compounds used in our assays 
were supplied by Biothera [PGG (soluble) and WGP (insoluble)] (Eaton, Minnesota). 
 
Preparation of Monocyte-Derived Macrophages from Human Blood (Figure 3):   
Monocyte-derived macrophages (MDMs) were isolated from human blood, according to 
the established protocol of the laboratory of Dr. Larry Schlesinger (26). Blood was drawn 
from healthy human donors (approved by IRB) using a syringe containing heparin 
(Abraxis Pharmaceutical Products, Schaumburg , IL) to prevent clotting, and then 
transferred to a 50 ml conical tube containing Normal Saline solution (1:1 v/v) to which 
was gently added Ficoll-Hypaque solution (Amersham Biosciences, Sweden) to form a 
layer at the bottom of the tube.  The tubes were centrifuged at 500 x g for 40 minutes at 
room temperature to separate the “buffy coat” layer containing peripheral blood 
mononuclear cells (PBMCs) from the bottom layer containing red blood cells (RBCs), 
neutrophils and platelets and the top layer containing serum.  The PBMCs were carefully 
removed, pooled together and washed twice in cold RPMI medium, by centrifuging first 
at 500 x g and then at 150 x g for 10 min each.  The supernatant was aspirated and the 
cell pellet was resuspended in a minimal volume of RPMI (usually 1/8th the volume of 
the original blood sample).  The cells were counted by using a hemocytometer and 
adjusted with RPMI containing 20% autologous serum to a concentration of 2 x 106 
PBMCs/ml.  The resulting cell suspension was transferred to Teflon wells and incubated 
at 37ºC/5% CO2 for 5 days to allow differentiation of PBMCs into MDMs.  Autologous 
serum was concurrently isolated from extra blood drawn from the same donor without 
using heparin.  Blood was allowed to clot in glass tubes at room temperature and then at 
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4ºC to allow separation of serum.  The serum was finally harvested by centrifugation at 
500 x g for 20 minutes at 4ºC.  
 After 5 day incubation, the PBMCs containing the differentiated population of 
MDMs (usually ~10% of the total PBMCs) were harvested from Teflon wells by several 
washes with cold RPMI and centrifugation at 150 x g for 10 min at 4ºC.  The 
supernatants were aspirated, the pellet was resuspended in a minimal volume of RPMI 
and the total cells were counted by hemocytometer.  The cell suspension was adjusted in 
RPMI containing 10% autologous serum to a concentration of 4 x 106 cells/ml and 
dispensed into a 24-well tissue culture plate (0.5 ml/well) with glass coverslips (Cell 
Association Assay) or without glass coverslips (Bacterial Survival Assay) in order to 
allow adherence of MDMs.  After incubation for 2-3 h at 37ºC/5% CO2, the adherent 
monolayer of MDMs (~2 x 105 cells/well) in each well was washed with warm RPMI in 
order to remove the non-adherent lymphocytes.  The cells were repleted with serum-free 
RHH (RPMI + 10mM Hepes + 1 mg/ml human serum albumin) medium for the Cell 
Association Assay or with RPMI containing 20% autologous serum for an additional 
incubation of 7 days for the β-Glucan Toxicity and Bacterial Survival Assays. 
 
Β-Glucan Toxicity Assays:  MDM monolayers in a 24-well tissue culture plate at Day 5 
were repleted with 20% serum-containing RPMI and incubated for 7 more days to ensure 
stable adherence of cells.  At Day 12, the macrophage monolayers were exposed to 
different concentrations of PGG or WGP (0, 6.25, 12.5, 25, 50 and 100 µg/ml in each 
case) in triplicate, in RPMI containing 1% serum (serum concentration was changed to 
2% for Survival Assays).  The morphology of the MDM monolayer was checked daily 
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for a period of five days under an inverted microscope and pictures taken to examine the 
toxicity of the β-glucan compound on macrophages.  MDM viability was also assessed 
by using 0.4% Trypan Blue Exclusion Staining (Sigma) at the end of the 5-day period.   
 
 Preparation of Mycobacterial Single Cell  Suspension for Infection:  This protocol 
(known as “Third Tube Protocol”) was established in Dr. Schlesinger’s laboratory.  
Loopfuls of freshly-grown (10-12 days) M. bovis BCG from a 7H11 agar plate were re-
suspended in 1.0 ml of RHH medium in an O-ring tube (Fisher Scientific) containing two 
ethanol-flamed glass beads.  The tube was pulse-vortexed three times and allowed to sit 
undisturbed at room temperature for 30 min.  The upper portion of the suspension (~700 
μl) was removed, transferred to a second O-ring tube and allowed to settle for 5 min.  The 
upper portion of the suspension (~600 μl) was again transferred to a third tube.  Dilutions 
were made of the final suspension and bacterial cells were counted by using a Petroff-
Hausser counting chamber (Hausser Scientific, Horsham, PA).  The bacterial suspension 
was adjusted in RHH to a concentration of 4 x 107 bacteria/ml for the Cell Association 
Assay and 4 x 106 bacteria/ml for the Bacterial Survival Assay.   
 
Cell Association Assay:   Monolayers of 5 day-old MDMs on coverslips in a 24-well 
tissue culture plate were washed with warm RPMI, repleted with 450 μl RHH containing 
50 µg/ml of β-glucan PGG or WGP and incubated for 30 min at 37ºC/5% CO2.  Then, 50 
μl of an M. bovis BCG single cell suspension (4 x 107 bacteria/ml) was added to each well 
(Multiplicity of Infection or MOI = 10:1 bacteria per cell) and incubated with shaking for 
30 min at 37ºC/5% CO2, followed by an additional incubation without shaking for 90 
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minutes at 37ºC/5% CO2 (total 2 h).  The infected monolayer was washed with warm 
RPMI and fixed with 10% formalin (Sigma, St. Louis, MO) in PBS buffer for 10 min.  
The monolayer was then washed with PBS and kept at 4ºC until Auramine-Rhodamine 
Staining.  Fixed MDM monolayers on coverslips were flooded with Auramine-
Rhodamine stain (Becton, Dickinson and Company, Sparks, MD) and incubated at room 
temperature in the dark for 20 min. The coverslips were dipped in H2O to stop staining 
and covered with acid-alcohol (700 ml 100% ethanol + 5 g NaCl + 300 ml deonized H2O 
+ 5 ml conc. HCl) for 3 min in the dark.  The coverslips were rinsed again in H2O, 
flooded with 0.5% KMnO4 for 2 min and finally mounted with 50% glycerol on slides.  
The non-β-glucan control, PGG- and WGP-pretreated MDM-containing coverslips were 
used in triplicate for each test group.  In each group, the MDM-associated M. bovis BCG 
bacterial cells were counted ( ≥ 300 MDMs) under a fluorescent microscope (Olympus 
BX51) and reported as average bacteria/macrophage. One tailed t-tests were performed to 
determine the significance of the results between groups.   
Mycobacterial Survival Assay:  Monolayers of 12 day-old MDMs in a 24-well tissue 
culture plate were washed with warm RPMI, repleted with 450 μl RHH containing 50 
µg/ml of β-glucan PGG or WGP and incubated for 30 min at 37ºC/5% CO2.  Then, 50 μl 
of an M. bovis BCG single cell suspension (4 x 106 bacteria/ml) was added to each well 
(MOI = 1:1 bacteria per cell) and incubated with shaking for 30 min at 37ºC/5% CO2, 
followed by an additional incubation without shaking for 90 minutes at 37ºC/5% CO2 
(total 2 h).  The infected monolayer was washed with warm RPMI, repleted in RPMI 
containing 2.0% autologous serum and incubated at 37ºC/5% CO2 for different time 
periods (24 h, 48 h, 72 h).  At the end of each time period, the supernatant from each well 
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was pipetted into an O-ring tube and centrifuged at 4ºC (10,000 x g) for 10 min.  The 
pellet was resuspended in 560 μl 7H9 broth at room temperature.  Ice-cold sterile dH2O 
(300 µl) containing 500 μg/ml of DNase was added to each well and let stand for 10 min.  
The resuspended pellet in 7H9 was added to its corresponding well along with 240 μl of 
0.25% SDS solution in PBS.  The plate was periodically shaken for 10 min in order to 
ensure complete lysis of the MDM monolayers.  Then, 300 μl of 20% Bovine Serum 
Albumin (BSA) in PBS was added to each well for neutralization.  The contents of each 
well were placed into an O-ring tube with two flame-sterilized glass beads and pulse-
vortexed five times.  Appropriate dilutions (usually, 20, 40, 80, 160) of the lysates were 
made in 7H9 containing OADC (Oleic Acid-Dextrose-Catalase) and plated on 7H11 agar 
quadrant plates.  The plates were incubated at 37ºC/5% CO2 until bacterial colonies 
appeared (18- 21 days) which were counted as colony forming units (CFUs).  The non-β-
glucan control, PGG- and WGP-pretreated MDM test groups were performed in 
triplicate.  CFUs were determined for each group and averages were used to perform one 
tailed t-tests to assess the significance of the results between test groups.   
 
 
 
Results: 
 
Beta-Glucan Toxicity of Human Macrophages:  The toxicity of PGG and WGP on the 
MDM monolayer was tested for a period of 5 days using different β-glucan 
concentrations (6.25, 12.5, 25, 50, and 100 µg/ml for each) in the medium.  MDM 
monolayers without the addition of a β-glucan preparation were used as the control.  Cell 
morphology and the integrity of the monolayer were checked daily under an inverted 
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microscope and cell death was finally examined by Trypan Blue Exclusion staining at the 
end of the 5-day period.  Results showed that both PGG and WGP at any concentration 
had no toxic effect on MDMs at day 1 and 2.  Figure 4 shows no difference in cell 
morphology between the control groups and the PGG- and WGP-pretreated groups. 
However, at day 3, the MDM monolayer treated with 100 µg/ml of WGP showed partial 
lifting and progressively more cell death through Day 5.  At this time point, WGP (100 
µg/ml) proved to be either completely or partially toxic to the monolayers, while all other 
monolayers appeared healthy throughout the five-day period (Figure 5).  Trypan Blue 
Exclusion staining of cell monolayers at day 5 showed a similar pattern of results as 
observed by microscopy (Table 1).  At day 5, about 80% cell death was caused by the use 
of 100 µg/ml WGP, while only 9% cell death occurred at 50 µg/ml.  All other WGP 
concentrations exhibited no cellular death.  PGG at 100 µg/ml showed 6% cell death only 
at day 5, while all other concentrations of PGG showed no effect on the MDM 
monolayer.  These results were used to choose an appropriate concentration of β-glucan 
preparation for bacterial cell association and survival assays.   
M. bovis BCG Association with β-Glucan-Treated Human Macrophages:  Cell 
association experiments were performed by using MDMs from two different donors       
(n = 2) with and without β-glucan in triplicate wells for each test group.  β-glucan (PGG 
or WGP) was used at 50 µg/ml concentration.  Both experiments showed similar trends 
with respect to decreased M. bovis BCG association with macrophages pre-treated with 
β-glucan preparations (Figures 6A and 7A).  In Experiment 1, the association results for 
β-glucan-treated MDMs were examined by determining the percent association when 
compared to the non-glucan control.  In Figure 6B, the percent of control comparison 
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shows a significant (P < 0.0001) decrease (35%) in bacterial association with PGG-
treated MDMs.  Similarly, WGP-treated MDMs show a significant (P < 0.005) decrease 
(43%) in M. bovis BCG association compared to the non-β-glucan control.  Experiment 2, 
using a different donor, produced similar results demonstrating the reproducibility of the 
assay.  The percent of control results (Figure 7B) for both PGG- and WGP-treated 
MDMs show decreased bacterial association (33% for both) with macrophages and are 
statistically significant (PGG, P = 0.0005; WGP, P < 0.005).  These results show that β-
glucan limits bacterial binding to and uptake into the macrophage, perhaps through pre-
engagement of the macrophage receptor CR3 by β-glucan particles.  
 
M. bovis BCG Survival in β-Glucan-Treated Human Macrophages:  A mycobacterial 
survival assay was performed by infecting β-glucan-treated MDMs wth M. bovis BCG 
and allowing bacterial replication within macrophages over a 3-day period. Each day 
post-infection, the infected MDMs were lysed, plated on agar medium, colonies counted 
after 21 days and expressed in CFUs/ml (Figure 8).  At 24 h and 48 h post-infection, 
there was no significant difference in the number of CFUs of M. bovis BCG between the 
β-glucan-treated and non-treated groups (Figure 8A and 8B).  However, 72 h post-
infection, a significant decrease in CFUs was observed in the β-glucan-treated groups 
compared to the control group (Figure 8C).  Figure 8D shows a growth curve of M. bovis 
BCG over the 3-day period.  The CFU results at 72 h were then examined by determining 
the percent CFUs of both β-glucan groups compared to the non-glucan control (Figure 
8E).  The percent control results for PGG and WGP CFUs show a significant decrease in 
M. bovis BCG survival in macrophages by 54% (P < 0.005) and 74% (P < 0.001), 
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respectively.  These results show an anti-mycobacterial activity conferred by human 
macrophages when treated with β-glucans.   
 
 
Discussion:   
M.tb is an intracellular pathogen which is highly adapted to evade host defense 
mechanisms and replicate within alveolar macrophages.  The gradual increase in MDR-
TB and the recent emergence of XDR-TB throughout the world add to the difficulty in 
controlling TB disease.  Patients with MDR-TB have a fatality rate of 40-60%, the same 
rate of death for non-treated TB cases (14).  The increasing rate of drug-resistant forms of 
TB highlights the need for new therapies to combat the disease.  Recently 1,3/1,6-β-D-
glucan particles have been identified as an agent in cancer treatment.  Studies have shown 
that β-glucan binds to CR3 on leukocytes in a non-opsonic manner and stimulates 
cytotoxic activation of C3bi-opsonized tumor cells by CR3 (35).  Without β-glucan 
binding, CR3 is unable to mediate lysis of C3bi-opsonized tumor cells (33).  These 
findings show one mechanism by which β-glucan particles promote anti-tumor activities.   
Yeast-derived 1,3/1,6-β-D-glucans have also been shown to stimulate immune 
responses and microbicidal activities.  Mice pre-treated with β-glucan showed an 
increased leukocyte count along with increased production of TNF-α and IL-6 pro-
inflammatory cytokines and respiratory burst (9,20).  In recent studies, β-glucans showed 
a protective effect against S. pneumoniae when mice were treated with β-glucan prior to 
or after infection with the bacteria (12).  Similarly, PGG and WGP have been shown to 
have a protective effect against anthrax infection, caused by the bacterium Bacillus 
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anthracis (19).  Intravenously injected β-glucan particles significantly reduced the 
bacterial load within the lungs of mice, while also increasing the survival rate of the 
animal.  
Our findings show a similar protective effect of PGG and WGP on human 
macrophages from M. bovis BCG infection.  Decreased cellular association and bacterial 
survival within MDMs were seen in the presence of β-glucan particles (Figures 6 through 
8).  The survival assay shows that MDM microbicidal activity against M. bovis BCG is 
enhanced in the presence of PGG and WGP (Figure 8).  Less bacterial survival within 
macrophages reduces the pathogen’s ability to replicate and cause infection in a host.  
The decreased effect that β-glucan has on cellular association also limits the 
pathogenicity of M. bovis BCG.  Without binding to and entry into the macrophage, M. 
bovis BCG and presumably M.tb strains have less ability to evade host defense 
mechanisms, since intracellular replication is a key to effective infection.   
Although no mechanisms of killing were investigated in our study, prior 
investigations give us insight to speculate about the function that the β-glucans have on 
human macrophages when infected with mycobacterial strains.   Increased TNF-α 
production is known to stimulate inflammatory responses along with increased nitric 
oxide and respiratory burst activities (25).  Fungal pathogens are recognized by alveolar 
macrophages through interaction with the β-glucan receptor Dectin-1, resulting in 
increased inflammatory responses (31). Dectin-1 is thought to work in co-operation with 
TLR-2 to stimulate TNF-α production (36).  The pre-incubation of MDMs with β-glucan 
allows for binding of this carbohydrate to Dectin-1 on the macrophage surface, resulting 
in the increased production of pro-inflammatory responses which could be the major 
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cause of bactericidal killing of M. bovis BCG in our study (Figure 8).  As stated above, β-
glucan also primes CR3 on leukocytes for cytotoxic killing of C3bi-opsonized particles in 
mice (35).  Although not much is known about M.tb’s pathogenic dependency on CR3, it 
has been reported that the bacterium is phagocytosed by macrophages in a C3bi-opsonic 
manner (5). It is possible that β-glucan particles bind to and activate CR3 to lyse M. bovis 
BCG, resulting in decreased survival of the bacteria within MDMs. The pre-occupation 
of CR3 (especially, its lectin-binding site) on MDMs by β-glucan is likely responsible for 
reduced association of M. bovis BCG with MDMs as observed in our study (Figures 6 
and 7). 
When compared to monocytes from patients with active TB, monocytes from 
MDR-TB patients show a decrease in TNF-α and NO production after infection with 
M.tb (28).  It is now generally agreed that M.tb infection dampens the host immune 
response and allows the bacterium to replicate inside the host cell.  TNF-α has been 
demonstrated as a key component in eliciting the protective host immune response to TB 
infection (25).  Since β-glucan is known to stimulate TNF-α production through binding 
to Dectin-1, this complex carbohydrate could initiate an immune response to defend 
against MDR-TB.  The data suggest the possibility that β-glucans may act as an agent to 
control the increasing rate of drug-resistant TB strains, where boosting of host immunity 
is the only alternative to the use of antibiotics.  
To our knowledge, this study was the first to test the effects of β-glucan on 
mycobacterial survival in human macrophages, and the slow-growing M. bovis BCG was 
used here as a model for the TB bacillus.  Because of the physiological and genomic 
similarities between M. bovis BCG and M.tb, these results indicate promising effects for 
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the potential protective role of β-glucans for M.tb infection of human macrophages.  The 
use of human macrophages is crucial in testing and validation of β-glucans as a possible 
therapeutic agent.  One of the future directions of our project will be to study the effects 
of PGG and WGP on human alveolar macrophages infected with virulent M.tb strains. 
Treatment of macrophages with β-glucan at different time points after infection with      
M.tb will also be done in the future study as the post-infection period is the time when 
drugs are administered to patients.  Though further investigations are needed, our 
preliminary results provide evidence for potential use of β-glucans as an alternative 
therapeutic agent to control the spread of TB.   
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Figures: 
 
 
               (Small and Fujiwara, 2001) 
 
Figure 1- Tuberculosis (TB) disease pathogenesis.  The first step in TB disease is 
transmission of the causative bacterium, Mycobacterium tuberculosis (M.tb).  
Transmission occurs when aerosol droplets containing M.tb from an individual with 
active TB in the lungs are deposited into the lungs of a healthy host.  Primary TB 
infection causes lesions in the lungs and elsewhere called granulomas by recruiting 
activated immune cells.  The host’s immune system is able to suppress replication of the 
bacterium and cause healing, leading to latent TB.  Latent TB can then lead to 
“reactivation” TB if the individual’s immune system is compromised, resulting in 
uncontrolled replication of M.tb (29).  
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Figure 2- β-glucan structures.  β-glucans are polysaccharides with a main chain 1,3-D-
glucopyranose and 1,6-D-glucopyranose branches.  Poly-1-6-β-D-glucopyranosyl-1-3-β-
D-glucopyranose (PGG) is a soluble form of β-glucan commonly used as a therapy for 
selected human diseases.  Whole glucan particle (WGP) is the insoluble form of PGG.   
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Figure 3- Methods of isolation and infection of monocyte-derived macrophages (MDMs) 
with M. bovis BCG.  Peripheral Blood Mononuclear Cells (PBMCs) were isolated on 
Day 0 from human donors and incubated for 5 days to allow differentiation into MDMs. 
At day 5, MDM monolayers were adhered to coverslips (Bacterial Association Assay), or 
incubated for another 7 days for performing the Bacterial Survival Assay.  Each assay 
involved 30 min pre-incubation of MDMs with either PGG or WGP and 2 h incubation 
with M. bovis BCG.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 23 -
Non- Glucan Control
PGG (100 μg/ml)
WGP (100 μg/ml)
 
 
 
Figure 4 – Human macrophage monolayers at day 1 of exposure to β-glucan 
preparations.  Day-1 MDM monolayers appeared healthy and intact for all concentrations 
of PGG and WGP.  There was no noticeable change in morphology of MDMs between 
the non-glucan- and β-glucan-treated groups.   
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WGP (100 µg/ml): partially toxic WGP (100 µg/ml): completely  toxic  
 
 
Figure 5- Human macrophage monolayers at day 5 of exposure to β-glucan preparations.  
At Day 5, WGP (100 μg/ml) proved partially or completely toxic for the MDMs.  All 
other concentrations of WGP had no significant effect on the monolayer.  However, 
MDM pre-treatment with all concentrations of PGG exhibited no significant effect on the 
monolayer compared to the non-glucan control.  
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Table 1 
 
PGG 0.0 0
6.25 0
12.5 0
25.0 0
50.0 0
100.0 6
WGP 0.0 0
6.25 0
12.5 0
25.0 0
50.0 9
100.0 80
β-Glucan Concentration Mean Cell Death*
(µg/ml) (%)
 
*Mean of duplicate wells (200 cells)  
 
 
0.4% Trypan Blue Staining was used to assess cellular death in β-glucan pre-treated 
MDM monolayers at day 5.  WGP (100 μg/ml) showed high toxicity for human 
macrophages with nearly 80% cell death at Day 5.  All other concentrations of PGG and 
WGP had little or no effect on macrophage death.   
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Figure 6- M. bovis BCG association with β-glucan treated MDMs (Experiment 1).  
MDMs in each well (2 x 105 cells) of a 24-well tissue culture plate were incubated at 
37ºC/5% CO2 in the absence or presence of PGG or WGP (50 μg/ml).  MDMs were then 
infected with 2 x 106 M. bovis BCG (MOI = 10:1) at 37ºC/5% CO2 for 2 h.  The infection 
was stopped and the cells were fixed.  Auramine Rhodamine staining was performed and 
cell-associated bacteria were counted under a fluorescence microscope.  A) Mean 
Bacteria/Cell Association: β-glucan stimulation caused significantly less cellular 
association of M. bovis BCG with human macrophages compared to the non-glucan 
control; B) Percent of Control Comparison: Compared to the non-glucan control, PGG 
and WGP significantly reduced bacterial association with MDMs.   
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Figure 7- M. bovis BCG association with β-glucan treated MDMs (Experiment 2).  
MDMs in each well (2 x 105 cells) of a 24-well tissue culture plate were incubated at 
37ºC/5% CO2 in the absence or presence of PGG or WGP (50 μg/ml). MDMs were then 
infected with 2 x 106 M. bovis BCG (MOI = 10:1) at 37ºC/5% CO2 for 2 h.  The infection 
was stopped and the cells were fixed.  Auramine Rhodamine staining was performed and 
cell-associated bacteria were counted under a fluorescence microscope.  A) Mean 
Bacteria/Cell Association:  β-glucan stimulation caused significantly decreased cellular 
association of M. bovis BCG with human macrophages compared to the non-glucan 
control; B) Percent of Control Comparison:  Compared to the non-glucan control, both 
PGG and WGP significantly reduced the association of M. bovis BCG with MDMs.   
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Figure 8- M. bovis BCG survival within β-glucan treated MDMs.  MDMs in each well (2 
x 105 cells) of a 24-well tissue culture plate were incubated at 37ºC/5% CO2 in the 
absence or presence of PGG or WGP (50 μg/ml).  MDMs were then infected with 2 x 105 
M. bovis BCG (MOI = 1:1) and incubated at 37ºC/5% CO2 for 2 h.  The infection was 
stopped with washing of the non-adherent bacteria and the cells were incubated in RPMI 
+ 2.0 % autologous serum for 24 h, 48 h or 72 h.  At each time point, cells were lysed and 
lysates plated on 7H11 agar in different dilutions and incubated at 37ºC/5% CO2 for 
growth.  Bacterial colonies were counted at 21 days and expressed in CFU/ml.  A and B) 
CFUs of M. bovis BCG were not affected by PGG or WGP 24 h or 48 h post-infection 
periods;  C) At 72 h, CFUs were significantly decreased in the presence of PGG and 
WGP, indicating decreased intracellular survival of M. bovis BCG in macrophages 
treated with β-glucan. D) The growth curve of M. bovis BCG shows inhibition of growth 
at 72 h in PGG and WGP pre-treated macrophages compared to the non-glucan control.  
E) Percent of Control Comparison: Compared to the non-glucan control, both PGG and 
WGP treatment showed a significant decrease in bacterial growth in MDMs.   
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